リキッドバイオプシーの世界市場レポート2026-2032

QY Research > レポート一覧 > 医療機器と消耗材 > リキッドバイオプシーの世界市場レポート2026-2032

英文タイトル： Global Liquid Biopsy Market Outlook, In‑Depth Analysis & Forecast to 2032

レポートID：1882687
発表時期：2026-07-17
訪問回数：468
ページ数：146
レポート形式：PDF
レポート言語：英語、日本語
グラフ数：155
レポートカテゴリ：医療機器と消耗材

販売価格（消費税別）

個人版
詳細
マルチユーザー版
詳細
企業版
詳細

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.50円。
※米ドル表示価格+10％消費税。

英語版

日本語版

英語と日本語版

価格表記: USDを日本円(税抜)に換算，本日の銀行送金レート: 1USD=162.50円。
※米ドル表示価格+10％消費税。

お見積

サンプルお申込み

お問い合わせ

今すぐ購入

※ご注文方法：お問い合わせフォームまたはメールにてご連絡ください。
支払方法：「銀行振込」の場合，注文の確認後、ご指定のメールアドレスに電子版の請求書をお送りいたしますので、電子版の請求書の記載事項に従って送金操作を行ってください。
※納期：原則として、受注後2～4営業日以内に発送いたします。但し、日本語版が必要な場合は、受注後8～10営業日となります。お客様のニーズに合わせて、事前にご注文のスケジュールをお立てください。

概要

本報告書は、リキッドバイオプシーの世界市場について、容量、生産量、収益、価格の概要を紹介します。2021年から2025年までの過去の市場収益/売上データ、2026年の予測データ、ならびに2032年までのCAGR（年平均成長率）予測を含む、世界市場動向の分析を提供します。本レポートは、メーカー、地域、製品種類、およびエンドユーザー産業の観点から、世界と主要地域の市場現状と将来性を研究したものです。世界と主要地域のトップメーカーを分析し、製品タイプおよびアプリケーション/エンドユーザー産業別にリキッドバイオプシー市場を分類しています。

本レポートでは、世界のリキッドバイオプシー市場の主要参加企業として、企業概要、販売数量、収益、価格、粗利益率、製品ポートフォリオ、地理的位置、主要な事業展開を以下のパラメータに基づいて紹介します。
本レポートはリキッドバイオプシーの主要生産者を調査するとともに、主要地域や国の消費状況も提供します。リキッドバイオプシーの主要地域／国における将来の市場ポテンシャルを重点的に分析し、それに基づき、異なるセグメントおよびサブセグメントにおける市場の将来動向を予測しております。アメリカ、カナダ、中国、アジア、ヨーロッパ、中東、アフリカ、ラテンアメリカ、その他の国々について、各国データおよび市場価値分析を提供しております。
2021年から2032年までの期間について、タイプ別および用途別の売上高、収益、価格に基づくセグメントデータを分析します。

本研究に含まれる主な企業は以下の通りです：
Guardant Health
Grail
Natera
Roche
Roche Diagnostics
Qiagen
Bio-Rad
Thermo Fisher Scientific
Exact Sciences
Illumina
Burning Rock Biotech
Novogen
Berry Oncology
BGI
MDxHealth
NeoGenomics Laboraories
Myriad Genetics
Aide Bio

タイプ別市場セグメント：
ctDNA Test
CTC Test
Exosome Test
Cell-free RNA Test
Other

用途別市場セグメント：
Hospitals Labs
Reference Labs
Other

地域別の市場セグメント：
北米
アジア太平洋
欧州
中南米
中東・アフリカ

本レポートの詳細内容：
世界のリキッドバイオプシー市場の現状と将来展望を包括的に分析し、グローバル主要地域における開発動向の綿密な調査を通じて、企業様に包括的な市場分析を提示します。市場の全体像を把握するため、プレイヤー、地域、製品タイプ、最終産業を網羅した多角的な分析を提供しています。さらに、世界市場のトッププレイヤーを特定し、プロファイルを作成するとともに、製品タイプや用途/最終産業に基づいてリキッドバイオプシー市場を細分化しています。この分類と用途分析により、市場の構造とダイナミクスをより深く理解することができ、情報に基づいた意思決定と戦略立案が可能になります。
一. 生産面では、2021年から2026年までの実績と2032年までの予測として、メーカー別、地域別（地域レベル、国レベル）のリキッドバイオプシー生産量、成長率、市場シェアを調査しています。
二. 消費面では、リキッドバイオプシーの売上高について、地域別（地域レベル・国レベル）、企業別、種類別、用途別に焦点を当てています。2021年から2026年まで、および2032年までの予測を対象とします。
三. 主要メーカーのリキッドバイオプシー売上高、収益、市場シェア、業界ランキングについて、2021年から2026年までのデータに焦点を当てています。世界のリキッドバイオプシー市場における主要なステークホルダーの特定、最近の動向とセグメント収益に基づく競争状況と市場ポジショニングの分析を行います。
四. 本リキッドバイオプシーレポートは、関係者が市場の競争状況を包括的に理解し、事業戦略や市場戦略を的確に立案するのに役立つ洞察を提供することを目的としています。売上高、成長動向、生産技術、用途、エンドユーザー産業に関する市場規模の詳細な評価と予測を提供し、意思決定者に強力なデータサポートを提供します。
章節目次：
第1章：リキッドバイオプシーレポートの範囲、市場セグメント（タイプ別、用途別など）ごとの市場規模、将来の発展可能性などをまとめたエグゼクティブサマリーをご紹介いたします。これにより、市場の最新状況を包括的に把握し、短期・中期・長期（2021-2032年）にわたる発展の見通しを把握いただけます。
第2章：リキッドバイオプシーの世界および主要生産者（地域／国別）の生産量／アウトプットについて分析します。各生産者の生産量と今後6年間の発展可能性を定量的に分析しています（2021年～2032年）
第3章：リキッドバイオプシーの現在の市場状況を提示し、2032年までの世界的な収益・販売・生産を予測するとともに、消費量の多い地域と新興市場の成長要因を特定します（2021年～2032年）
第4章：リキッドバイオプシーメーカーの競争状況、価格、売上高、収益、市場シェア、業界ランキング、最新の開発計画、合併・買収情報など詳細に分析します（2021年～2026年）
第5章：リキッドバイオプシーの下流市場機会を特定し、用途別販売量・収益・価格設定を評価するとともに新興ユースケースを明らかにし、地域別・用途別の主要顧客をプロファイリングします
第6章：リキッドバイオプシーのグローバル生産能力、稼働率、市場シェア（2021-2032年）をマッピングし、効率的拠点を特定するとともに規制や貿易政策の影響とボトルネックを解明します
第7章：北米におけるリキッドバイオプシー市場をアプリケーション別・国別売上高・収益で分析し、主要メーカーをプロファイリングしつつ成長要因と障壁を評価します
第8章：欧州におけるリキッドバイオプシー市場をアプリケーション別・メーカー別に地域別売上高・収益・市場分析を行い、成長要因と障壁を明示します
第9章：アジア太平洋地域のリキッドバイオプシー市場を用途別・地域/国別の売上高と収益で定量化し、主要メーカーをプロファイリングするとともに高成長潜在地域を明らかにします
第10章：中南米におけるリキッドバイオプシー市場を用途別・国別売上高と収益で測定し、主要メーカーをプロファイリングするとともに投資機会と課題を特定します
第11章：中東・アフリカ地域のリキッドバイオプシー市場を用途別・国別に評価し、主要メーカーをプロファイリングするとともに投資見通しと市場障壁を概説します
第12章：リキッドバイオプシーの主要メーカーの概要を提供し、製品説明、売上高、収益、価格、粗利益率、最近の事業拡大などの情報を整理するとともに、SWOT分析および戦略動向分析を行います
第13章：リキッドバイオプシーのサプライチェーンを分析し、上流の原材料・供給業者、製造拠点と技術、コスト要因を明らかにします
第14章：リキッドバイオプシーの市場動向、最新動向、推進要因と制約要因、業界内のメーカーが直面する課題とリスク、関連する業界政策の分析を紹介します
第15章：レポートの要点と結論
第16章：付録

Description

The global Liquid Biopsy market is projected to grow from US$ 4587 million in 2025 to US$ 15796 million by 2032, at a CAGR of 19.2% (2026-2032), driven by critical product segments and diverse end‑use applications.

Liquid biopsy is a molecular diagnostic technology that detects tumor-related biomarkers in body fluids such as blood, urine, or cerebrospinal fluid to enable disease screening, diagnosis, treatment monitoring, and recurrence surveillance. Compared with conventional tissue biopsy, liquid biopsy offers significant advantages including minimal invasiveness, repeatable sampling, and the ability to perform real-time dynamic monitoring. The technology primarily analyzes circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), exosomes, and tumor-derived RNA using advanced analytical platforms such as next-generation sequencing and digital PCR. Liquid biopsy provides a more comprehensive view of tumor molecular characteristics and heterogeneity, making it an important tool in precision medicine. With continuous advancements in genomic technologies, bioinformatics, and the growing demand for early cancer detection, liquid biopsy is increasingly becoming a key component of modern oncology diagnostics and translational research.The average gross profit margin of this product is 65%.

The continuous evolution of precision medicine is transforming clinical practice from empirical treatment toward molecular classification and personalized therapy, creating significant opportunities for liquid biopsy technologies. Increasing demand for sensitive molecular diagnostics in cancer screening, targeted therapy, and immunotherapy has positioned liquid biopsy as a critical bridge between diagnostics and treatment decision-making. Meanwhile, the declining cost of sequencing technologies and improvements in bioinformatics capabilities are enhancing the accessibility and scalability of liquid biopsy applications. Global pharmaceutical companies and research institutions are also increasing investments in early cancer detection and companion diagnostics, further accelerating technological innovation and commercialization in this field.

Despite its strong potential, liquid biopsy still faces several technical and regulatory challenges in clinical adoption. The extremely low concentration of tumor-derived molecules in body fluids requires highly sensitive and specific detection technologies, placing stringent demands on experimental workflows, analytical platforms, and data interpretation. In addition, the lack of standardized methodologies across different testing platforms may affect result consistency and clinical interpretation. Regulatory requirements for molecular diagnostic products are also becoming more rigorous, and the need for extensive clinical validation can lengthen the approval and commercialization process, potentially slowing market penetration.

Downstream demand for liquid biopsy is gradually expanding from late-stage cancer monitoring to broader clinical applications. Early cancer screening, treatment response evaluation, minimal residual disease detection, and recurrence monitoring are becoming increasingly important application areas. As precision oncology strategies continue to evolve, clinicians are relying more on dynamic molecular testing to guide treatment decisions, strengthening the role of liquid biopsy in clinical workflows. In addition, biopharmaceutical companies are increasingly adopting liquid biopsy technologies as companion diagnostic tools and research instruments in drug development, making them valuable in clinical trials and real-world evidence studies.

The upstream segment of the liquid biopsy industry mainly includes nucleic acid extraction reagents, sample preservation and stabilization reagents, sequencing reagents, and high-sensitivity molecular detection consumables. These materials directly influence detection sensitivity, stability, and experimental reproducibility, making them fundamental to overall test performance. As molecular diagnostics technologies continue to evolve, reagent suppliers are developing more efficient nucleic acid enrichment solutions and high-stability reagents to meet the demands of ultra-low concentration biomarker detection. Continuous improvements in automated sample processing systems and high-performance sequencing platforms are also driving technological advancement and scalability across the entire industry chain.

Report Includes:
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Liquid Biopsy market across value chain. It analyzes historical revenue data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.

By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.

Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.

Critical competitive intelligence profiles players (revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.

A concise Industry‑chain overview maps upstream, middle stream, and downstream distribution dynamics to identify strategic gaps and unmet demand.

Market Segmentation
By Company
Guardant Health
Grail
Natera
Roche
Roche Diagnostics
Qiagen
Bio-Rad
Thermo Fisher Scientific
Exact Sciences
Illumina
Burning Rock Biotech
Novogen
Berry Oncology
BGI
MDxHealth
NeoGenomics Laboraories
Myriad Genetics
Aide Bio

Segment by Type
ctDNA Test
CTC Test
Exosome Test
Cell-free RNA Test
Other

Segment by Technology Platform
NGS Sequencing
Digital PCR
Real-time PCR
Other

Segment by Sample
Blood Sample
Urine Sample
Other

Segment by Application
Hospitals Labs
Reference Labs
Other

Segment by Region
North America
United States
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
Australia
Vietnam
Indonesia
Malaysia
Philippines
Singapore
Rest of Asia
Europe
Germany
U.K.
France
Italy
Spain
Benelux
Russia
Rest of Europe
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East & Africa
GCC Countries
Egypt
Israel
South Africa
Rest of MEA

Chapter Outline
Chapter 1: Defines the Liquid Biopsy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape: ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down market size by Application and country, profiles key players and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional market by Application and players, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies market size by Application, and region/country, profiles top players, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures market size by Application, and country, profiles top players, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates market size by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth: details product specs, revenue, margins; top-tier players 2025 sales breakdowns by product type, by Application, by region SWOT analysis, and recent strategic developments
Chapter 12: Value chain and ecosystem: analyses upstream, midstream, plus downstream channels
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).

Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.

Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).

Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).

Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

Table of Contents

1 Study Coverage
1.1 Introduction to Liquid Biopsy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Liquid Biopsy Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 ctDNA Test
1.2.3 CTC Test
1.2.4 Exosome Test
1.2.5 Cell-free RNA Test
1.2.6 Other
1.3 Market Segmentation by Technology Platform
1.3.1 Global Liquid Biopsy Market Size by Technology Platform, 2021 vs 2025 vs 2032
1.3.2 NGS Sequencing
1.3.3 Digital PCR
1.3.4 Real-time PCR
1.3.5 Other
1.4 Market Segmentation by Sample
1.4.1 Global Liquid Biopsy Market Size by Sample, 2021 vs 2025 vs 2032
1.4.2 Blood Sample
1.4.3 Urine Sample
1.4.4 Other
1.5 Market Segmentation by Application
1.5.1 Global Liquid Biopsy Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Hospitals Labs
1.5.3 Reference Labs
1.5.4 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Liquid Biopsy Revenue Estimates and Forecasts (2021-2032)
2.2 Global Liquid Biopsy Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends

3 Competitive Landscape
3.1 Global Liquid Biopsy Players’ Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2021-2026)
3.1.2 Global Key Players’ Revenue Ranking (2024 vs 2025)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Players (2021 vs 2025)
3.2 Global Liquid Biopsy Companies Headquarters and Service Footprint
3.3 Key Player Market Share by Product Type
3.3.1 ctDNA Test: Market Share by Key Players
3.3.2 CTC Test: Market Share by Key Players
3.3.3 Exosome Test: Market Share by Key Players
3.3.4 Cell-free RNA Test: Market Share by Key Players
3.3.5 Other: Market Share by Key Players
3.4 Global Liquid Biopsy Market Concentration and Dynamics
3.4.1 Global Market Concentration
3.4.2 Market Entry and Exit Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment

4 Product Segmentation
4.1 Global Liquid Biopsy Market by Type
4.1.1 Global Revenue by Type (2021-2032)
4.1.2 Global Revenue-Based Market Share by Type (2021-2032)
4.2 Global Liquid Biopsy Market by Technology Platform
4.2.1 Global Revenue by Technology Platform (2021-2032)
4.2.2 Global Revenue-Based Market Share by Technology Platform (2021-2032)
4.3 Global Liquid Biopsy Market by Sample
4.3.1 Global Revenue by Sample (2021-2032)
4.3.2 Global Revenue-Based Market Share by Sample (2021-2032)
4.4 Key Product Attributes and Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Liquid Biopsy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.1.2 Revenue-Based Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application

6 North America
6.1 North America Market Size (2021-2032)
6.2 North America Key Players’ Revenue in 2025
6.3 North America Liquid Biopsy Market Size by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Liquid Biopsy Market Size by Country
6.5.1 North America Revenue Trends by Country
6.5.2 US
6.5.3 Canada
6.5.4 Mexico

7 Europe
7.1 Europe Market Size (2021-2032)
7.2 Europe Key Players’ Revenue in 2025
7.3 Europe Liquid Biopsy Market Size by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Liquid Biopsy Market Size by Country
7.5.1 Europe Revenue Trends by Country
7.5.2 Germany
7.5.3 France
7.5.4 U.K.
7.5.5 Italy
7.5.6 Russia

8 Asia-Pacific
8.1 Asia-Pacific Market Size (2021-2032)
8.2 Asia-Pacific Key Players’ Revenue in 2025
8.3 Asia-Pacific Liquid Biopsy Market Size by Application (2021-2032)
8.4 Asia-Pacific Growth Accelerators and Market Barriers
8.5 Asia-Pacific Liquid Biopsy Market Size by Region
8.5.1 Asia-Pacific Revenue Trends by Region
8.6 China
8.7 Japan
8.8 South Korea
8.9 Australia
8.10 India
8.11 Southeast Asia
8.11.1 Indonesia
8.11.2 Vietnam
8.11.3 Malaysia
8.11.4 Philippines
8.11.5 Singapore

9 Central and South America
9.1 Central and South America Market Size (2021-2032)
9.2 Central and South America Key Players’ Revenue in 2025
9.3 Central and South America Liquid Biopsy Market Size by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Liquid Biopsy Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Market Size (2021-2032)
10.2 Middle East and Africa Key Players’ Revenue in 2025
10.3 Middle East and Africa Liquid Biopsy Market Size by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Liquid Biopsy Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Israel
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Guardant Health
11.1.1 Guardant Health Corporation Information
11.1.2 Guardant Health Business Overview
11.1.3 Guardant Health Liquid Biopsy Product Features and Attributes
11.1.4 Guardant Health Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.1.5 Guardant Health Liquid Biopsy Revenue by Product in 2025
11.1.6 Guardant Health Liquid Biopsy Revenue by Application in 2025
11.1.7 Guardant Health Liquid Biopsy Revenue by Geographic Area in 2025
11.1.8 Guardant Health Liquid Biopsy SWOT Analysis
11.1.9 Guardant Health Recent Developments
11.2 Grail
11.2.1 Grail Corporation Information
11.2.2 Grail Business Overview
11.2.3 Grail Liquid Biopsy Product Features and Attributes
11.2.4 Grail Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.2.5 Grail Liquid Biopsy Revenue by Product in 2025
11.2.6 Grail Liquid Biopsy Revenue by Application in 2025
11.2.7 Grail Liquid Biopsy Revenue by Geographic Area in 2025
11.2.8 Grail Liquid Biopsy SWOT Analysis
11.2.9 Grail Recent Developments
11.3 Natera
11.3.1 Natera Corporation Information
11.3.2 Natera Business Overview
11.3.3 Natera Liquid Biopsy Product Features and Attributes
11.3.4 Natera Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.3.5 Natera Liquid Biopsy Revenue by Product in 2025
11.3.6 Natera Liquid Biopsy Revenue by Application in 2025
11.3.7 Natera Liquid Biopsy Revenue by Geographic Area in 2025
11.3.8 Natera Liquid Biopsy SWOT Analysis
11.3.9 Natera Recent Developments
11.4 Roche
11.4.1 Roche Corporation Information
11.4.2 Roche Business Overview
11.4.3 Roche Liquid Biopsy Product Features and Attributes
11.4.4 Roche Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.4.5 Roche Liquid Biopsy Revenue by Product in 2025
11.4.6 Roche Liquid Biopsy Revenue by Application in 2025
11.4.7 Roche Liquid Biopsy Revenue by Geographic Area in 2025
11.4.8 Roche Liquid Biopsy SWOT Analysis
11.4.9 Roche Recent Developments
11.5 Roche Diagnostics
11.5.1 Roche Diagnostics Corporation Information
11.5.2 Roche Diagnostics Business Overview
11.5.3 Roche Diagnostics Liquid Biopsy Product Features and Attributes
11.5.4 Roche Diagnostics Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.5.5 Roche Diagnostics Liquid Biopsy Revenue by Product in 2025
11.5.6 Roche Diagnostics Liquid Biopsy Revenue by Application in 2025
11.5.7 Roche Diagnostics Liquid Biopsy Revenue by Geographic Area in 2025
11.5.8 Roche Diagnostics Liquid Biopsy SWOT Analysis
11.5.9 Roche Diagnostics Recent Developments
11.6 Qiagen
11.6.1 Qiagen Corporation Information
11.6.2 Qiagen Business Overview
11.6.3 Qiagen Liquid Biopsy Product Features and Attributes
11.6.4 Qiagen Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.6.5 Qiagen Recent Developments
11.7 Bio-Rad
11.7.1 Bio-Rad Corporation Information
11.7.2 Bio-Rad Business Overview
11.7.3 Bio-Rad Liquid Biopsy Product Features and Attributes
11.7.4 Bio-Rad Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.7.5 Bio-Rad Recent Developments
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Corporation Information
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Liquid Biopsy Product Features and Attributes
11.8.4 Thermo Fisher Scientific Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.8.5 Thermo Fisher Scientific Recent Developments
11.9 Exact Sciences
11.9.1 Exact Sciences Corporation Information
11.9.2 Exact Sciences Business Overview
11.9.3 Exact Sciences Liquid Biopsy Product Features and Attributes
11.9.4 Exact Sciences Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.9.5 Exact Sciences Recent Developments
11.10 Illumina
11.10.1 Illumina Corporation Information
11.10.2 Illumina Business Overview
11.10.3 Illumina Liquid Biopsy Product Features and Attributes
11.10.4 Illumina Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.10.5 Company Ten Recent Developments
11.11 Burning Rock Biotech
11.11.1 Burning Rock Biotech Corporation Information
11.11.2 Burning Rock Biotech Business Overview
11.11.3 Burning Rock Biotech Liquid Biopsy Product Features and Attributes
11.11.4 Burning Rock Biotech Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.11.5 Burning Rock Biotech Recent Developments
11.12 Novogen
11.12.1 Novogen Corporation Information
11.12.2 Novogen Business Overview
11.12.3 Novogen Liquid Biopsy Product Features and Attributes
11.12.4 Novogen Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.12.5 Novogen Recent Developments
11.13 Berry Oncology
11.13.1 Berry Oncology Corporation Information
11.13.2 Berry Oncology Business Overview
11.13.3 Berry Oncology Liquid Biopsy Product Features and Attributes
11.13.4 Berry Oncology Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.13.5 Berry Oncology Recent Developments
11.14 BGI
11.14.1 BGI Corporation Information
11.14.2 BGI Business Overview
11.14.3 BGI Liquid Biopsy Product Features and Attributes
11.14.4 BGI Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.14.5 BGI Recent Developments
11.15 MDxHealth
11.15.1 MDxHealth Corporation Information
11.15.2 MDxHealth Business Overview
11.15.3 MDxHealth Liquid Biopsy Product Features and Attributes
11.15.4 MDxHealth Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.15.5 MDxHealth Recent Developments
11.16 NeoGenomics Laboraories
11.16.1 NeoGenomics Laboraories Corporation Information
11.16.2 NeoGenomics Laboraories Business Overview
11.16.3 NeoGenomics Laboraories Liquid Biopsy Product Features and Attributes
11.16.4 NeoGenomics Laboraories Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.16.5 NeoGenomics Laboraories Recent Developments
11.17 Myriad Genetics
11.17.1 Myriad Genetics Corporation Information
11.17.2 Myriad Genetics Business Overview
11.17.3 Myriad Genetics Liquid Biopsy Product Features and Attributes
11.17.4 Myriad Genetics Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.17.5 Myriad Genetics Recent Developments
11.18 Aide Bio
11.18.1 Aide Bio Corporation Information
11.18.2 Aide Bio Business Overview
11.18.3 Aide Bio Liquid Biopsy Product Features and Attributes
11.18.4 Aide Bio Liquid Biopsy Revenue and Gross Margin (2021-2026)
11.18.5 Aide Bio Recent Developments

12 Liquid Biopsy Value Chain and Ecosystem Analysis
12.1 Liquid Biopsy Value Chain (Ecosystem Structure)
12.2 Upstream Analysis
12.2.1 Key Technologies, Platforms and Infrastructure
12.3 Midstream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Liquid Biopsy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints

14 Key Findings in the Global Liquid Biopsy Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

Table of Figures

List of Tables
 Table 1. Global Liquid Biopsy Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
 Table 2. Global Liquid Biopsy Market Size Growth Rate by Technology Platform, 2021 vs 2025 vs 2032 (US$ Million)
 Table 3. Global Liquid Biopsy Market Size Growth Rate by Sample, 2021 vs 2025 vs 2032 (US$ Million)
 Table 4. Global Liquid Biopsy Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
 Table 5. Global Liquid Biopsy Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 6. Global Liquid Biopsy Revenue by Region (US$ Million), 2021-2026
 Table 7. Global Liquid Biopsy Revenue by Region (US$ Million), 2027-2032
 Table 8. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
 Table 9. Global Liquid Biopsy Revenue by Players (US$ Million), 2021-2026
 Table 10. Global Liquid Biopsy Revenue-Based Market Share by Players (2021-2026)
 Table 11. Global Key Players’Ranking Shift (2024 vs 2025) (Based on Revenue)
 Table 12. Global Companies by Tier (Tier 1, Tier 2, and Tier 3), based on Liquid Biopsy Revenue, 2025
 Table 13. Global Liquid Biopsy Average Gross Margin (%) by Player (2021 vs 2025)
 Table 14. Global Liquid Biopsy Companies Headquarters
 Table 15. Global Liquid Biopsy Market Concentration Ratio (CR5)
 Table 16. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
 Table 17. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
 Table 18. Global Liquid Biopsy Revenue by Type (US$ Million), 2021-2026
 Table 19. Global Liquid Biopsy Revenue by Type (US$ Million), 2027-2032
 Table 20. Global Liquid Biopsy Revenue by Technology Platform (US$ Million), 2021-2026
 Table 21. Global Liquid Biopsy Revenue by Technology Platform (US$ Million), 2027-2032
 Table 22. Global Liquid Biopsy Revenue by Sample (US$ Million), 2021-2026
 Table 23. Global Liquid Biopsy Revenue by Sample (US$ Million), 2027-2032
 Table 24. Key Product Attributes and Differentiation
 Table 25. Global Liquid Biopsy Revenue by Application (US$ Million), 2021-2026
 Table 26. Global Liquid Biopsy Revenue by Application (US$ Million), 2027-2032
 Table 27. Liquid Biopsy High-Growth Sectors Demand CAGR (2026-2032)
 Table 28. Top Customers by Region
 Table 29. Top Customers by Application
 Table 30. North America Liquid Biopsy Growth Accelerators and Market Barriers
 Table 31. North America Liquid Biopsy Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
 Table 32. Europe Liquid Biopsy Growth Accelerators and Market Barriers
 Table 33. Europe Liquid Biopsy Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
 Table 34. Asia-Pacific Liquid Biopsy Growth Accelerators and Market Barriers
 Table 35. Asia-Pacific Liquid Biopsy Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Table 36. Central and South America Liquid Biopsy Investment Opportunities and Key Challenges
 Table 37. Central and South America Liquid Biopsy Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
 Table 38. Middle East and Africa Liquid Biopsy Investment Opportunities and Key Challenges
 Table 39. Middle East and Africa Liquid Biopsy Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
 Table 40. Guardant Health Corporation Information
 Table 41. Guardant Health Description and Major Businesses
 Table 42. Guardant Health Product Features and Attributes
 Table 43. Guardant Health Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 44. Guardant Health Revenue Proportion by Product in 2025
 Table 45. Guardant Health Revenue Proportion by Application in 2025
 Table 46. Guardant Health Revenue Proportion by Geographic Area in 2025
 Table 47. Guardant Health Liquid Biopsy SWOT Analysis
 Table 48. Guardant Health Recent Developments
 Table 49. Grail Corporation Information
 Table 50. Grail Description and Major Businesses
 Table 51. Grail Product Features and Attributes
 Table 52. Grail Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 53. Grail Revenue Proportion by Product in 2025
 Table 54. Grail Revenue Proportion by Application in 2025
 Table 55. Grail Revenue Proportion by Geographic Area in 2025
 Table 56. Grail Liquid Biopsy SWOT Analysis
 Table 57. Grail Recent Developments
 Table 58. Natera Corporation Information
 Table 59. Natera Description and Major Businesses
 Table 60. Natera Product Features and Attributes
 Table 61. Natera Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 62. Natera Revenue Proportion by Product in 2025
 Table 63. Natera Revenue Proportion by Application in 2025
 Table 64. Natera Revenue Proportion by Geographic Area in 2025
 Table 65. Natera Liquid Biopsy SWOT Analysis
 Table 66. Natera Recent Developments
 Table 67. Roche Corporation Information
 Table 68. Roche Description and Major Businesses
 Table 69. Roche Product Features and Attributes
 Table 70. Roche Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 71. Roche Revenue Proportion by Product in 2025
 Table 72. Roche Revenue Proportion by Application in 2025
 Table 73. Roche Revenue Proportion by Geographic Area in 2025
 Table 74. Roche Liquid Biopsy SWOT Analysis
 Table 75. Roche Recent Developments
 Table 76. Roche Diagnostics Corporation Information
 Table 77. Roche Diagnostics Description and Major Businesses
 Table 78. Roche Diagnostics Product Features and Attributes
 Table 79. Roche Diagnostics Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 80. Roche Diagnostics Revenue Proportion by Product in 2025
 Table 81. Roche Diagnostics Revenue Proportion by Application in 2025
 Table 82. Roche Diagnostics Revenue Proportion by Geographic Area in 2025
 Table 83. Roche Diagnostics Liquid Biopsy SWOT Analysis
 Table 84. Roche Diagnostics Recent Developments
 Table 85. Qiagen Corporation Information
 Table 86. Qiagen Description and Major Businesses
 Table 87. Qiagen Product Features and Attributes
 Table 88. Qiagen Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 89. Qiagen Recent Developments
 Table 90. Bio-Rad Corporation Information
 Table 91. Bio-Rad Description and Major Businesses
 Table 92. Bio-Rad Product Features and Attributes
 Table 93. Bio-Rad Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 94. Bio-Rad Recent Developments
 Table 95. Thermo Fisher Scientific Corporation Information
 Table 96. Thermo Fisher Scientific Description and Major Businesses
 Table 97. Thermo Fisher Scientific Product Features and Attributes
 Table 98. Thermo Fisher Scientific Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 99. Thermo Fisher Scientific Recent Developments
 Table 100. Exact Sciences Corporation Information
 Table 101. Exact Sciences Description and Major Businesses
 Table 102. Exact Sciences Product Features and Attributes
 Table 103. Exact Sciences Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 104. Exact Sciences Recent Developments
 Table 105. Illumina Corporation Information
 Table 106. Illumina Description and Major Businesses
 Table 107. Illumina Product Features and Attributes
 Table 108. Illumina Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 109. Illumina Recent Developments
 Table 110. Burning Rock Biotech Corporation Information
 Table 111. Burning Rock Biotech Description and Major Businesses
 Table 112. Burning Rock Biotech Product Features and Attributes
 Table 113. Burning Rock Biotech Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 114. Burning Rock Biotech Recent Developments
 Table 115. Novogen Corporation Information
 Table 116. Novogen Description and Major Businesses
 Table 117. Novogen Product Features and Attributes
 Table 118. Novogen Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 119. Novogen Recent Developments
 Table 120. Berry Oncology Corporation Information
 Table 121. Berry Oncology Description and Major Businesses
 Table 122. Berry Oncology Product Features and Attributes
 Table 123. Berry Oncology Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 124. Berry Oncology Recent Developments
 Table 125. BGI Corporation Information
 Table 126. BGI Description and Major Businesses
 Table 127. BGI Product Features and Attributes
 Table 128. BGI Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 129. BGI Recent Developments
 Table 130. MDxHealth Corporation Information
 Table 131. MDxHealth Description and Major Businesses
 Table 132. MDxHealth Product Features and Attributes
 Table 133. MDxHealth Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 134. MDxHealth Recent Developments
 Table 135. NeoGenomics Laboraories Corporation Information
 Table 136. NeoGenomics Laboraories Description and Major Businesses
 Table 137. NeoGenomics Laboraories Product Features and Attributes
 Table 138. NeoGenomics Laboraories Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 139. NeoGenomics Laboraories Recent Developments
 Table 140. Myriad Genetics Corporation Information
 Table 141. Myriad Genetics Description and Major Businesses
 Table 142. Myriad Genetics Product Features and Attributes
 Table 143. Myriad Genetics Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 144. Myriad Genetics Recent Developments
 Table 145. Aide Bio Corporation Information
 Table 146. Aide Bio Description and Major Businesses
 Table 147. Aide Bio Product Features and Attributes
 Table 148. Aide Bio Revenue (US$ Million) and Gross Margin (2021-2026)
 Table 149. Aide Bio Recent Developments
 Table 150. Technologies, Platforms and Infrastructure
 Table 151. Distributors List
 Table 152. Market Trends and Market Evolution
 Table 153. Market Drivers and Opportunities
 Table 154. Market Challenges, Risks, and Restraints
 Table 155. Research Programs/Design for This Report
 Table 156. Key Data Information from Secondary Sources
 Table 157. Key Data Information from Primary Sources


List of Figures
 Figure 1. Global Liquid Biopsy Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
 Figure 2. ctDNA Test Product Picture
 Figure 3. CTC Test Product Picture
 Figure 4. Exosome Test Product Picture
 Figure 5. Cell-free RNA Test Product Picture
 Figure 6. Other Product Picture
 Figure 7. Global Liquid Biopsy Market Size Growth Rate by Technology Platform, 2021 vs 2025 vs 2032 (US$ Million)
 Figure 8. NGS Sequencing Product Picture
 Figure 9. Digital PCR Product Picture
 Figure 10. Real-time PCR Product Picture
 Figure 11. Other Product Picture
 Figure 12. Global Liquid Biopsy Market Size Growth Rate by Sample, 2021 vs 2025 vs 2032 (US$ Million)
 Figure 13. Blood Sample Product Picture
 Figure 14. Urine Sample Product Picture
 Figure 15. Other Product Picture
 Figure 16. Global Liquid Biopsy Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
 Figure 17. Hospitals Labs
 Figure 18. Reference Labs
 Figure 19. Other
 Figure 20. Liquid Biopsy Report Years Considered
 Figure 21. Global Liquid Biopsy Revenue, (US$ Million), 2021 vs 2025 vs 2032
 Figure 22. Global Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 23. Global Liquid Biopsy Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
 Figure 24. Global Liquid Biopsy Revenue-Based Market Share by Region (2021-2032)
 Figure 25. Global Liquid Biopsy Revenue-Based Market Share Ranking (2025)
 Figure 26. Tier Distribution by Revenue Contribution (2021 vs 2025)
 Figure 27. ctDNA Test Revenue-Based Market Share by Player in 2025
 Figure 28. CTC Test Revenue-Based Market Share by Player in 2025
 Figure 29. Exosome Test Revenue-Based Market Share by Player in 2025
 Figure 30. Cell-free RNA Test Revenue-Based Market Share by Player in 2025
 Figure 31. Other Revenue-Based Market Share by Player in 2025
 Figure 32. Global Liquid Biopsy Revenue-Based Market Share by Type (2021-2032)
 Figure 33. Global Liquid Biopsy Revenue-Based Market Share by Technology Platform (2021-2032)
 Figure 34. Global Liquid Biopsy Revenue-Based Market Share by Sample (2021-2032)
 Figure 35. Global Liquid Biopsy Revenue-Based Market Share by Application (2021-2032)
 Figure 36. North America Liquid Biopsy Revenue YoY (US$ Million), 2021-2032
 Figure 37. North America Top 5 Players Liquid Biopsy Revenue (US$ Million) in 2025
 Figure 38. North America Liquid Biopsy Revenue (US$ Million) by Application (2021-2032)
 Figure 39. US Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 40. Canada Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 41. Mexico Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 42. Europe Liquid Biopsy Revenue YoY (US$ Million), 2021-2032
 Figure 43. Europe Top 5 Players Liquid Biopsy Revenue (US$ Million) in 2025
 Figure 44. Europe Liquid Biopsy Revenue (US$ Million) by Application (2021-2032)
 Figure 45. Germany Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 46. France Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 47. U.K. Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 48. Italy Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 49. Russia Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 50. Asia-Pacific Liquid Biopsy Revenue YoY (US$ Million), 2021-2032
 Figure 51. Asia-Pacific Top 8 Players Liquid Biopsy Revenue (US$ Million) in 2025
 Figure 52. Asia-Pacific Liquid Biopsy Revenue (US$ Million) by Application (2021-2032)
 Figure 53. Indonesia Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 54. Japan Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 55. South Korea Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 56. Australia Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 57. India Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 58. Indonesia Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 59. Vietnam Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 60. Malaysia Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 61. Philippines Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 62. Singapore Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 63. Central and South America Liquid Biopsy Revenue YoY (US$ Million), 2021-2032
 Figure 64. Central and South America Top 5 Players Liquid Biopsy Revenue (US$ Million) in 2025
 Figure 65. Central and South America Liquid Biopsy Revenue (US$ Million) by Application (2021-2032)
 Figure 66. Brazil Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 67. Argentina Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 68. Middle East and Africa Liquid Biopsy Revenue YoY (US$ Million), 2021-2032
 Figure 69. Middle East and Africa Top 5 Players Liquid Biopsy Revenue (US$ Million) in 2025
 Figure 70. Middle East and Africa Liquid Biopsy Revenue (US$ Million) by Application (2021-2032)
 Figure 71. GCC Countries Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 72. Israel Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 73. Egypt Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 74. South Africa Liquid Biopsy Revenue (US$ Million), 2021-2032
 Figure 75. Liquid Biopsy Value Chain Mapping
 Figure 76. Channels of Distribution (Direct Vs Distribution)
 Figure 77. Bottom-up and Top-down Approaches for This Report
 Figure 78. Data Triangulation
 Figure 79. Key Executives Interviewed

以下、関連資料のご紹介